Search Results - "Runyon, John Paul"

A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia by LOSORDO, Douglas W, KIBBE, Melina R, CARMAN, Teresa, DOHAD, Suhail, HUANG, Paul, JUNGE, Candice E, STORY, Kenneth, WEISTROFFER, Tara, THORNE, Tina M, MILLAY, Meredith, RUNYON, John Paul, SCHAINFELD, Robert, MENDELSOHN, Farrell, MARSTON, William, DRIVER, Vickie R, SHARAFUDDIN, Melhem, TEODORESCU, Victoria, WIECHMANN, Bret N, THOMPSON, Charles, KRAISS, Larry

“…Critical limb ischemia portends a risk of major amputation of 25% to 35% within 1 year of diagnosis. Preclinical studies provide evidence that intramuscular…”
Get full text

Midterm Outcomes from the TALON Registry: Treating Peripherals with SilverHawk: Outcomes Collection by Ramaiah, Venkatesh, Gammon, Roger, Kiesz, Stefan, Cardenas, Joseph, Runyon, John Paul, Fail, Peter, Walker, Craig, Allie, David E., Chamberlin, Jack, Solis, Maurice, Garcia, Lawrence, Kandzari, David

“…Purpose: To determine midterm clinical outcomes among patients with lower extremity peripheral arterial disease who underwent revascularization with…”
Get full text

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention by Kereiakes, Dean J, Broderick, Thomas M, Roth, Eli M, Whang, David, Shimshak, Thomas, Runyon, John Paul, Hattemer, Charles, Schneider, John, Lacock, Pam, Mueller, Michele, Abbottsmith, Charles W

“…Adjunctive platelet glycoprotein IIb/IIIa blockade during percutaneous coronary intervention (PCI) reduces platelet-mediated adverse ischemic outcomes…”
Get full text

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials by Lincoff, A.Michael, LeNarz, LeRoy A, Despotis, George J, Smith, Peter K, Booth, Joan E, Raymond, Russell E, Sapp, Shelly K, Cabot, Catherine F, Tcheng, James E, Califf, Robert M, Effron, Mark B, Topol, Eric J

“…Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk…”
Get full text

Midterm Outcomes From the TALON Registry: T reating Peripher a ls With Si l verHawk: O utcomes Collectio n by Ramaiah, Venkatesh, Gammon, Roger, Kiesz, Stefan, Cardenas, Joseph, Runyon, John Paul, Fail, Peter, Walker, Craig, Allie, David E., Chamberlin, Jack, Solis, Maurice, Garcia, Lawrence, Kandzari, David

Get full text

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa Receptor Blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized Trial by KEREIAKES, D. J, KLEIMAN, N. S, HANTSBARGER, G. L, BRYZINSKI, B, TOPOL, E. J, FERGUSON, J. J, ZAKI MASUD, A. R, BRODERICK, T. M, ABBOTTSMITH, C. W, RUNYON, J. P, ANDERSON, L. C, ANDERS, R. J, DREILING, R. J

“…Parenteral administration of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor blockers can reduce ischemic complications of coronary angioplasty. Orally…”
Get full text

Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion by Kereiakes, Dean J., Essell, James H., Abbottsmith, Charles W., Broderick, Thomas M., Runyon, John Paul

“…In summary, first time abciximab administration was associated with acute profound thrombocytopenia in 4 of 575 consecutive patients. Therapy with platelet…”
Get full text

IIb’s are not IIb’s by Kereiakes, Dean J., Runyon, John Paul, Broderick, Thomas M., Shimshak, Thomas M.

“…Platelet glycoprotein (GP) IIb/IIIa receptor blockade improves clinical outcomes after percutaneous coronary intervention (PCI) and for patients who present…”
Get full text

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment by KEREIAKES, D. J, KLEIMAN, N, FERGUSON, J. J, RUNYON, J. P, BRODERICK, T. M, HIGBY, N. A, MARTIN, L. H, HANTSBARGER, G, MCDONALD, S, ANDERS, R. J

“…Inhibition of platelet aggregation with parenteral glycoprotein (GP) IIb/IIIa receptor blockers can reduce the ischemic complications of angioplasty. Sustained…”
Get full text

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab : Administration for complex coronary intervention by KEREIAKES, D. J, RUNYON, J. P, KLEIMAN, N. S, HIGBY, N. A, ANDERSON, L. C, HANTSBARGER, G, MCDONALD, S, ANDERS, R. J

“…Placebo-controlled randomized trials of parenteral platelet glycoprotein (GP) IIb/IIIa receptor antagonists have demonstrated reduced ischemic complications of…”
Get full text

Abciximab provides cost-effective survival advantage in high-volume interventional practice by Kereiakes, Dean J., Obenchain, Robert L., Barber, Beth L., Smith, Andrew, McDonald, Mark, Broderick, Thomas M., Runyon, John Paul, Shimshak, Thomas M., Schneider, John F., Hattemer, Charles R., Roth, Eli M., Whang, David D., Cocks, Douglas, Abbottsmith, Charles W.

“…Background Placebo-controlled randomized trials of platelet glycoprotein (GP) IIb/IIIa blockade during percutaneous coronary intervention have demonstrated…”
Get full text

Rapid dissolution of intracoronary thrombus with eptifibatide therapy in a patient with post-infarction angina by Runyon, J P, Snavely, D D

Get more information

Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice by Young, John J, Marcus, Daniel P, Abbottsmith, Charles W, Broderick, Thomas M, Choo, Joseph K, Runyon, John Paul, Schneider, John F, Shimshak, Thomas M, Geier, Rodney P, Kereiakes, Dean J

“…Although randomized clinical trials have demonstrated efficacy of coronary irradiation versus placebo for the treatment of in-stent restenosis (ISR), durable…”
Get more information

Abciximab-associated profound thrombocytopenia : Therapy with immunoglobulin and platelet transfusion by KEREIAKES, D. J, ESSELL, J. H, ABBOTTSMITH, C. W, BRODERICK, T. M, RUNYON, J. P

“…First-time abciximab administration was associated with acute profound thrombocytopenia in 4 of 575 consecutive patients. Therapy with platelet transfusion,…”
Get full text